niacinamide has been researched along with Syndrome in 25 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC)." | 9.14 | [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. ( Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ, 2009) |
| "Patients with liver fibrosis/cirrhosis and hepatocellular carcinoma were treated with sorafenib 400 mg b." | 7.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| "Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis, having encouraging efficacy and tolerability in patients with metastatic renal cell carcinoma (RCC) and other tumors." | 6.47 | Sorafenib-associated hand-foot syndrome in Japanese patients. ( Adachi, M; Akaza, H; Fukino, K; Furuse, J; Iijima, M; Minami, H; Murai, M; Naito, S; Tsukamoto, T, 2011) |
| "Sorafenib (Nexavar) is a targeted therapy acting as VEGFR and PDGFR tyrosine-kinase inhibitor that has been approved in France in the treatment of metastatic renal cell carcinoma and hepatocarcinoma." | 5.35 | [Hand-foot syndrome and sorafenib]. ( Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A, 2009) |
| "To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC)." | 5.14 | [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. ( Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ, 2009) |
| " Our article focuses on the palmoplantar erythrodysesthesia syndrome, designated also as the hand-foot skin reaction (HFSR), which most frequently occurs in patients treated with TKI sorafenib and sunitinib." | 4.86 | [Hand-foot syndrome after administration of tyrosinkinase inhibitors]. ( Bednaríková, D; Kocák, I, 2010) |
| " This case report discusses an atypical presentation of the hand-foot syndrome in one patient treated with sorafenib." | 3.80 | Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy. ( Bella, A; Guerra, JR; Lolo, D; Suelves, AM, 2014) |
| "Patients with liver fibrosis/cirrhosis and hepatocellular carcinoma were treated with sorafenib 400 mg b." | 3.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| "One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied." | 2.90 | [Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome]. ( Esipov, AV; Ivolgin, AF; Kalyagin, IE; Karakozov, AG; Katenko, SV; Kazakov, SP; Khritinin, DF; Levchenko, OB; Molodova, AI, 2019) |
| "Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis, having encouraging efficacy and tolerability in patients with metastatic renal cell carcinoma (RCC) and other tumors." | 2.47 | Sorafenib-associated hand-foot syndrome in Japanese patients. ( Adachi, M; Akaza, H; Fukino, K; Furuse, J; Iijima, M; Minami, H; Murai, M; Naito, S; Tsukamoto, T, 2011) |
| "Sorafenib (Nexavar) is a targeted therapy acting as VEGFR and PDGFR tyrosine-kinase inhibitor that has been approved in France in the treatment of metastatic renal cell carcinoma and hepatocarcinoma." | 1.35 | [Hand-foot syndrome and sorafenib]. ( Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (20.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esipov, AV | 1 |
| Ivolgin, AF | 1 |
| Khritinin, DF | 1 |
| Katenko, SV | 1 |
| Kazakov, SP | 1 |
| Karakozov, AG | 1 |
| Kalyagin, IE | 1 |
| Levchenko, OB | 1 |
| Molodova, AI | 1 |
| Belov, VG | 1 |
| Parfenov, IuA | 1 |
| Okovityĭ, SV | 1 |
| Guerra, JR | 1 |
| Suelves, AM | 1 |
| Bella, A | 1 |
| Lolo, D | 1 |
| Markevich, PS | 1 |
| Markevich, LB | 1 |
| Plekhanov, AN | 1 |
| Kovalenko, AL | 1 |
| Chutko, LS | 1 |
| Surushkina, SY | 1 |
| Yakovenko, EA | 1 |
| Rozhkova, AV | 1 |
| Anisimova, TI | 1 |
| Bondarchuk, YL | 1 |
| Wolber, C | 1 |
| Udvardi, A | 1 |
| Tatzreiter, G | 1 |
| Schneeberger, A | 1 |
| Volc-Platzer, B | 1 |
| Milano, G | 1 |
| Mortier, L | 1 |
| Digue, L | 1 |
| Desmedt, E | 1 |
| Ravaud, A | 1 |
| Xu, L | 1 |
| Li, P | 1 |
| Lin, XJ | 1 |
| Yuan, YF | 1 |
| Zhang, YQ | 1 |
| Chen, MS | 1 |
| Lipworth, AD | 1 |
| Robert, C | 1 |
| Zhu, AX | 1 |
| Zhang, T | 1 |
| Ding, X | 1 |
| Wei, D | 1 |
| Cheng, P | 1 |
| Su, X | 1 |
| Liu, H | 1 |
| Wang, D | 1 |
| Gao, H | 1 |
| Bednaríková, D | 1 |
| Kocák, I | 1 |
| Iijima, M | 1 |
| Fukino, K | 1 |
| Adachi, M | 1 |
| Tsukamoto, T | 1 |
| Murai, M | 1 |
| Naito, S | 1 |
| Minami, H | 1 |
| Furuse, J | 1 |
| Akaza, H | 1 |
| Pinter, M | 1 |
| Sieghart, W | 1 |
| Reiberger, T | 1 |
| Rohr-Udilova, N | 1 |
| Ferlitsch, A | 1 |
| Peck-Radosavljevic, M | 1 |
| Rachid, MA | 1 |
| Demaula, CD | 1 |
| Scott, DW | 1 |
| Miller, WH | 1 |
| Senter, DA | 1 |
| Myers, S | 1 |
| THIERS, H | 1 |
| FORNAINI, G | 1 |
| PONTREMOLI, S | 1 |
| DRAGO, U | 1 |
| FINOTTO, E | 1 |
| MADDALOSSO, T | 1 |
| Moriwaka, F | 1 |
| Govindarajan, R | 1 |
| Adusumilli, J | 1 |
| Baxter, DL | 1 |
| El-Khoueiry, A | 1 |
| Harik, SI | 1 |
| Chung, CL | 1 |
| Cusack, CA | 1 |
| Chung, NM | 1 |
| Gutierrez, M | 1 |
| Turner, ML | 1 |
| Lai, SE | 1 |
| Kuzel, T | 1 |
| Lacouture, ME | 1 |
| LeWitt, PA | 1 |
| McDonald, MC | 1 |
| Filipe, HM | 1 |
| Thiemermann, C | 1 |
| Mys'ko, GN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330] | 129 participants (Actual) | Interventional | 2014-03-21 | Completed | |||
| "Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011] | Phase 3 | 72 participants (Actual) | Interventional | 2018-07-12 | Completed | ||
| The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625] | Phase 4 | 288 participants (Actual) | Interventional | 2016-01-28 | Completed | ||
| Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma[NCT00661375] | Phase 2 | 131 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and Syndrome
| Article | Year |
|---|---|
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2010 |
[Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; | 2010 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
[Nicotinic acid].
Topics: Dementia; Dermatitis; Diagnosis, Differential; Diarrhea; Humans; Niacin; Niacinamide; Pellagra; Synd | 2004 |
4 trials available for niacinamide and Syndrome
| Article | Year |
|---|---|
[Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome].
Topics: Administration, Oral; Antioxidants; Asthenia; Drug Combinations; Flavin Mononucleotide; Humans; Inos | 2019 |
[Treatment of alcohol addiction syndrome with cytoflavin].
Topics: Adult; Alcoholism; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Ma | 2013 |
[The efficacy of cytoflavin in the treatment of burnout syndrome].
Topics: Adult; Antioxidants; Burnout, Professional; Drug Combinations; Female; Flavin Mononucleotide; Humans | 2015 |
[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; | 2009 |
16 other studies available for niacinamide and Syndrome
| Article | Year |
|---|---|
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, He | 2014 |
[THE PHARMACOTHERAPEUTIC EFFICIENCY OF CYTOFLAVIN IN PATIENTS WITH DIABETIC FOOT SYNDROME: IMMEDIATE AND LONG-TERM RESULTS].
Topics: Adult; Aged; Diabetic Foot; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphos | 2015 |
Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
Topics: Aged; Angioedema; Antineoplastic Agents; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; | 2009 |
[Hand-foot syndrome and sorafenib].
Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neo | 2009 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirr | 2012 |
Concurrent follicular dysplasia and interface dermatitis in Boxer dogs.
Topics: Animals; Dermatitis; Dog Diseases; Dogs; Female; Folliculitis; Immunohistochemistry; Male; Niacinami | 2003 |
[Syndrome of ecchymoses of effort without urticaria; porphyrinuria, improvement with large doses of nicotinamide].
Topics: Ecchymosis; Humans; Niacin; Niacinamide; Nicotinic Acids; Porphyrias; Syndrome; Urticaria | 1952 |
[Acute biochemical syndrome caused by excessive doses of vitamin PP: activity of the transketolase and transaldolase reactions].
Topics: Niacin; Niacinamide; Nicotinic Acids; Syndrome; Transaldolase; Transferases; Transketolase | 1960 |
[CONSIDERATIONS ON THE USE OF CYANOCOBALAMINE IN HIGH DOSES BY PHLEBOCLYSIS (ASSOCIATED WITH PP VITAMIN, ASCORBIC ACID, FOLIC ACID) IN VARIOUS CLINICAL SITUATIONS (LIVER DISEASES, ANEMIC-DEFICIENT SYNDROMES)].
Topics: Adolescent; Anemia; Ascorbic Acid; Child; Corrinoids; Folic Acid; Geriatrics; Humans; Injections, In | 1965 |
Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cholangiocarcinoma; Clinical Trials as Topic; Enzyme Inh | 2006 |
Wells syndrome: an enigmatic and therapeutically challenging disease.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Inflammatory Age | 2006 |
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diagnosis, Different | 2006 |
Hand-foot and stump syndrome to sorafenib.
Topics: Amputation Stumps; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; | 2007 |
The neurotoxicity of the rat poison vacor. A clinical study of 12 cases.
Topics: Adult; Brain Diseases; Diabetes Mellitus; Humans; Hypotension, Orthostatic; Male; Middle Aged; Nervo | 1980 |
Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Benzamides; Blood Pressure; Creatine Kin | 1999 |
[Several indices of the methylation process in schizophrenic patients].
Topics: Adult; Antipsychotic Agents; Automatism; Catechol O-Methyltransferase; Depression; Female; Hallucina | 1977 |